

I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for the treatment of dry eye resulting from injury to corneal nerves, said method comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising at least one compound that promotes neuron regeneration or neurite outgrowth, wherein said compound is selected from the group consisting of propentofylline, AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 (1-(1-butyl)-4-(2-oxo-1-benzimidazole) piperidine, eliprodil, SR57746A (xaliproden hydrochloride) or pharmaceutically acceptable analogs thereof.

Claim 2 (original) The method of claim 1, wherein the injury to corneal nerves results from surgery.

Claim 3 (original) The method of claim 2, wherein the surgery is LASIK surgery.

Claim 4 (cancelled) The method of claim 1, wherein the compound may be selected from the group consisting of propentofylline, AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 (1-(1-butyl)-4-(2-oxo-1-benzimidazole) piperidine, eliprodil, SR57746A (xaliproden hydrochloride) or pharmaceutically acceptable analogs thereof.

Claim 5 (currently amended) The method of claim 4₁, wherein the compound is AIT-082.

Claim 6 (currently amended) The method of claim 4₁, wherein the compound is eliprodil.

Claim 7 (withdrawn) A method for the treatment of decrease in cornea sensitivity resulting from injury to corneal nerves, said method comprising administering to a patient in need thereof a therapeutically effective amount of at least one composition comprising a compound that promotes neuron regeneration or neurite outgrowth.

Claim 8 (withdrawn) The method of claim 7, wherein the injury to corneal nerves results from surgery.

Claim 9 (withdrawn) The method of claim 8, wherein the surgery is LASIK surgery.

Claim 10 (withdrawn) The method of claim 7, wherein the compound may be selected from the group consisting of propentofylline, AIT-082 (neotrofin), idebenone, ONO-2506,

CB-1093, NS521 (1-(1-butyl)-4-(2-oxo-1-benzimidazole) piperidine, eliprodil, SR57746A (xaliproden hydrochloride) or pharmaceutically acceptable analogs thereof.

Claim 11 (withdrawn) The method of claim 10, wherein the compound is AIT-082.

Claim 12 (withdrawn) The method of claim 10, wherein the compound is eliprodil.

Claim 13 (withdrawn) A method for the treatment of injury to corneal nerves comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a compound that promotes neuron regeneration or neurite outgrowth.

Claim 14 (withdrawn) The method of claim 13, wherein the injury to corneal nerves results from surgery.

Claim 15 (withdrawn) The method of claim 14, wherein the surgery is LASIK surgery.

Claim 16 (withdrawn) The method of claim 13, wherein the compound may be selected from the group consisting of propentofylline, AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 (1-(1-butyl)-4-(2-oxo-1-benzimidazole) piperidine, eliprodil, SR57746A (xaliproden hydrochloride) or pharmaceutically acceptable analogs thereof.

Claim 17 (withdrawn) The method of claim 16, wherein the compound is AIT-082.

Claim 18 (withdrawn) The method of claim 16, wherein the compound is eliprodil.